Gilead Sciences, a leading biopharmaceutical company, has recently published new data in the New England Journal of Medicine (NEJM) showcasing the positive outcomes of their investigational drugs, bulevirtide and domvanalimab, in treating chronic hepatitis delta virus (HDV) infection and upper gastrointestinal (GI) cancers, respectively.
In a Phase 2b MYR204 open-label study, Gilead Sciences evaluated the efficacy and safety of bulevirtide, a revolutionary entry inhibitor, as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN). The results, published in NEJM, demonstrate the potential of this combination to achieve post-treatment undetectable HDV RNA in adults living with compensated chronic HDV infection. The study’s positive outcomes provide hope for millions suffering from this debilitating condition.
Additionally, Gilead Sciences, in collaboration with Arcus Biosciences, presented the longer-term efficacy and safety data from Arm A1 of the Phase 2 EDGE-Gastric study. The study evaluated the potential of domvanalimab in combination with zimberelimab and chemotherapy as a first-line treatment for upper GI cancers, including gastric, gastroesophageal junction, and esophageal adenocarcinoma. The updated data showcased consistent response rate (ORR) and mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic tumors. These encouraging results mark an essential milestone in the development of novel treatment options for upper GI cancers.
Conclusion:
The latest clinical trial data published in NEJM highlights the significant strides Gilead Sciences has made in the field of medical research and treatment. The successful outcomes of bulevirtide in addressing chronic HDV infection and the promising results of domvanalimab in the treatment of upper GI cancers offer new avenues for patients and healthcare professionals to combat these challenging diseases.
Comments